The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.

about

Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.Corilagin induces the apoptosis of hepatocellular carcinoma cells through the mitochondrial apoptotic and death receptor pathways.

P2860

Q47932240-8ACE398F-5D32-4D34-8D80-FCC8818BC0E7 Q52716857-C4D99FDC-0E04-4801-8F2A-4BABF6ACF588

P2860

The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.

Item

http://www.wikidata.org/entity/Q38766548

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The Development and Current Us ...... Chronic Lymphocytic Leukemia.

@en

type

Item

label

The Development and Current Us ...... Chronic Lymphocytic Leukemia.

@en

prefLabel

The Development and Current Us ...... Chronic Lymphocytic Leukemia.

@en

P1476

The Development and Current Us ...... Chronic Lymphocytic Leukemia.

@en

P2093

Benjamin L Lampson

http://www.w3.org/2001/XMLSchema#string

Matthew S Davids

http://www.w3.org/2001/XMLSchema#string

P2860

PUMA, a novel proapoptotic gene, is induced by p53

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.

P2888

s11899-017-0359-0

P304

11-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-017-0359-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1074209071

http://www.w3.org/2001/XMLSchema#string

P698

28116634

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

P932

5862560

http://www.w3.org/2001/XMLSchema#string

The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.

about

P2860

P2860

The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932